PMID- 26998697
OWN - NLM
STAT- MEDLINE
DCOM- 20170529
LR  - 20191210
IS  - 1539-736X (Electronic)
IS  - 0022-3018 (Linking)
VI  - 204
IP  - 7
DP  - 2016 Jul
TI  - Effects of 3,4-Methylenedioxymethamphetamine on Patient Utterances in a 
      Psychotherapeutic Setting.
PG  - 519-23
LID - 10.1097/NMD.0000000000000499 [doi]
AB  - 3,4-Methylenedioxymethamphetamine (MDMA) administered as an adjunct to talk 
      therapy influences patient speech content and increases improvement in 
      treatment-resistant posttraumatic stress disorder (PTSD). Data came from the 
      recordings of Mithoefer et al. (2011). In the third therapeutic session studied, 
      patients were assigned, double blind, to an MDMA or a placebo group. 
      Condition-blind scorers listened to therapy recordings and scored utterances 
      where patients initiated topics that were empathic (regarding others' emotions), 
      entactic (requesting or appreciating physical touch), or ensuic (describing a 
      change in their sense of themselves). Patients who received MDMA produced high 
      levels of ensuic, empathic, and entactic utterances compared with those who 
      received the placebo. Interrater discourse scoring was reliable. The relationship 
      between the number of scored utterances and the Clinician Administered PTSD Scale 
      scores measuring PTSD severity after the treatment was significant, and 
      reanalysis grouped bimodally into "many" or "few" such utterances remained 
      significant. MDMA assisted these patients in having meaningful and 
      disorder-resolving thoughts and discourse in talk therapy.
FAU - Corey, Vicka Rael
AU  - Corey VR
AD  - *Harvard Medical School, Boston; daggerThe Laboratory for Integrative Psychiatry, 
      Division of Alcohol and Drug Abuse, McLean Hospital, Belmont; and double daggerClinical 
      Trials Network Institute, Massachusetts General Hospital, Boston.
FAU - Pisano, Vincent D
AU  - Pisano VD
FAU - Halpern, John H
AU  - Halpern JH
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - J Nerv Ment Dis
JT  - The Journal of nervous and mental disease
JID - 0375402
RN  - 0 (Serotonin Agents)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Adult
MH  - Combined Modality Therapy
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/administration & dosage/*pharmacology
MH  - Outcome Assessment, Health Care/*methods
MH  - Psychotherapy/*methods
MH  - Serotonin Agents/administration & dosage/*pharmacology
MH  - Stress Disorders, Post-Traumatic/drug therapy/*therapy
MH  - Verbal Behavior/*drug effects
EDAT- 2016/03/22 06:00
MHDA- 2017/05/30 06:00
CRDT- 2016/03/22 06:00
PHST- 2016/03/22 06:00 [entrez]
PHST- 2016/03/22 06:00 [pubmed]
PHST- 2017/05/30 06:00 [medline]
AID - 10.1097/NMD.0000000000000499 [doi]
PST - ppublish
SO  - J Nerv Ment Dis. 2016 Jul;204(7):519-23. doi: 10.1097/NMD.0000000000000499.